All In Biotech

Drug Trial Radar · NCT05769153

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants With Neovascular Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 139 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

139

Actual

Start

Dec 6, 2023

Primary completion

Apr 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Mar 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • AR-14034 SR implant lower doseDrug

    AR-14034 SR administered as an intravitreal implant

  • AR-14034 SR implant higher doseDrug

    AR-14034 SR administered as an intravitreal implant

  • AR-14034 SR implantDrug

    AR-14034 SR administered as an intravitreal implant

  • Aflibercept InjectionDrug

    Aflibercept administered as a 2 milligram (mg) intravitreal injection

  • Sham procedureDrug

    Needleless syringe used to simulate an intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in ETDRS BCVA at the average across two visits, Weeks 44 and 48 (Stage 2)Time frame: Baseline, Week 44, Week 48

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Trinity Research Group

    Dothan, Alabama

  • Associated Retina Consultants - Gilbert

    Gilbert, Arizona

  • Associated Retina Consultants - Phoenix

    Phoenix, Arizona

  • Retina Associates of SW PC

    Tucson, Arizona

  • The Retina Partners

    Encino, California

  • Retina Associates of Orange County

    Laguna Hills, California

  • Northern California Retina Vitreous Associates Medical Group

    Mountain View, California

  • Eye Research Foundation

    Newport Beach, California

  • Azul Vision Pasadena

    Pasadena, California

  • Retina Consultants of Southern Colorado

    Colorado Springs, Colorado

  • Retina Group of New England | Waterford

    Waterford, Connecticut

  • Florida Retina Institute

    Jacksonville, Florida

  • Mid Florida Eye Center

    Mt. Dora, Florida

  • Florida Retina Institute

    Orlando, Florida

  • Retina Specialty Institute

    Pensacola, Florida

  • Eye Associates of Pinellas

    Pinellas Park, Florida

  • Center for Retina and Macular Disease

    Winter Haven, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Thomas Eye Group Main Office

    Sandy Springs, Georgia

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Twin Cities Eye Consultants

    Coon Rapids, Minnesota

  • Mississippi Retina Associates

    Madison, Mississippi

  • Vision Research Center Eye Associates of New Mexico

    Albuquerque, New Mexico

  • NYC Retina - Queens

    Forest Hills, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Verum Research, LLC

    Eugene, Oregon

  • Erie Retina Research

    Erie, Pennsylvania

  • MidAtlantic Retina Research

    Philadelphia, Pennsylvania

  • Retina Consultants of Carolina

    Greenville, South Carolina

  • Carolina Eyecare Physicians LLC

    Mt. Pleasant, South Carolina

  • Retina Research Institute of Texas

    Abilene, Texas

  • Texas Retina Associates - Arlington

    Arlington, Texas

  • Austin Research Center for Retina

    Austin, Texas

  • Austin Retina Associates

    Austin, Texas

  • Austin Clinical Research, LLC

    Austin, Texas

  • Star Vision Research

    Burleson, Texas

  • Texas Retina Associates

    Dallas, Texas

  • Berkeley Eye Center

    Houston, Texas

  • Retina Consultants of Texas - San Antonio

    San Antonio, Texas

  • Austin Retina Associates (San Marcos)

    San Marcos, Texas

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.